Form 13-F position report

G1 THERAPEUTICS INC

Reported by DIMENSIONAL FUND ADVISORS LP

GTHX CUSIP 3621LQ109 Manager CIK 0000354204

Reported 74,408 shares, down 8,843 (10.6%) from the prior quarter.

Reported value -48.3%; share count -10.6% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2023
Shares 74,408 Quarter-end amount reported
Reported value $107,148 Fair value at quarter end
Consecutive quarters held 20 Through Q3 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 7911000
2021-12-31 5358000
2022-03-31 4302000
2022-06-30 2657000
2022-09-30 5825000
2022-12-31 1999000
2023-03-31 238878
2023-06-30 207295
2023-09-30 107148
2023-12-31 233831
2024-03-31 334933
2024-06-30 170604
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for G1 THERAPEUTICS INC held by DIMENSIONAL FUND ADVISORS LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -74,826 (-100.0%) 0 $0 2024-11-07
Q2 2024 Reduced 74,826 -2,705 (-3.5%) < 0.01% $170,604 2024-08-09
Q1 2024 Added 77,531 +865 (1.1%) < 0.01% $334,933 2024-05-10
Q4 2023 Added 76,666 +2,258 (3.0%) < 0.01% $233,831 2024-02-07
Q3 2023 Reduced 74,408 -8,843 (-10.6%) < 0.01% $107,148 2023-11-09
Q2 2023 Reduced 83,251 -5,882 (-6.6%) < 0.01% $207,295 2023-08-09
Q1 2023 Reduced 89,133 -278,836 (-75.8%) < 0.01% $238,878 2023-05-12
Q4 2022 Reduced 367,969 -98,461 (-21.1%) < 0.01% $1,999,000 2023-02-09
Q3 2022 Reduced 466,430 -71,557 (-13.3%) < 0.01% $5,825,000 2022-11-10
Q2 2022 Reduced 537,987 -28,024 (-5.0%) < 0.01% $2,657,000 2022-08-12
Q1 2022 Added 566,011 +41,278 (7.9%) < 0.01% $4,302,000 2022-05-13
Q4 2021 Reduced 524,733 -64,598 (-11.0%) < 0.01% $5,358,000 2022-02-09
Q3 2021 Reduced 589,331 -480,793 (-44.9%) < 0.01% $7,911,000 2021-11-12
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

89 managers reported G1 THERAPEUTICS INC for Q3 2023.

Managers reporting G1 THERAPEUTICS INC in Q3 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Unchanged 1,950,068 0 < 0.01% $2,808,098 26 qtrs
BlackRock Inc Reduced 1,120,307 -65,338 < 0.01% $1,613,240 26 qtrs
MILLENNIUM MANAGEMENT LLC Added 1,048,995 +440,930 < 0.01% $1,510,553 8 qtrs
RAYMOND JAMES & ASSOCIATES Added 925,776 +133,662 < 0.01% $1,333,117 16 qtrs
JACOBS LEVY EQUITY MANAGEMENT INC Added 573,256 +80,480 < 0.01% $825,489 6 qtrs
MARSHALL WACE LLP Added 516,728 +461,128 < 0.01% $744,089 7 qtrs
D E Shaw & Co Inc Reduced 505,082 -111,421 < 0.01% $727,318 6 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 474,080 -97,711 < 0.01% $683,000 6 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 440,633 +8,981 < 0.01% $634,678 26 qtrs
XTX Topco Ltd Added 296,601 +186,753 0.07% $427,105 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2023
Filed
November 09, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
31,667
Shared
12,902
None
29,839

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.